Brandes Investment Partners LP Grows Stock Holdings in Grifols, S.A. (NASDAQ:GRFS)

Brandes Investment Partners LP lifted its stake in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,496,093 shares of the biotechnology company's stock after purchasing an additional 592,096 shares during the period. Grifols comprises about 1.7% of Brandes Investment Partners LP's holdings, making the stock its 15th largest holding. Brandes Investment Partners LP owned about 2.98% of Grifols worth $152,491,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. R Squared Ltd acquired a new stake in Grifols in the fourth quarter valued at $28,000. GAMMA Investing LLC raised its stake in Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock valued at $37,000 after buying an additional 1,527 shares in the last quarter. Blue Trust Inc. raised its stake in Grifols by 254.0% in the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock valued at $52,000 after buying an additional 4,970 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Grifols in the fourth quarter valued at $91,000. Finally, HighTower Advisors LLC raised its stake in Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company's stock valued at $123,000 after buying an additional 1,546 shares in the last quarter.

Grifols Stock Performance

Shares of GRFS traded up $0.02 during midday trading on Wednesday, reaching $8.12. 521,280 shares of the stock were exchanged, compared to its average volume of 1,255,897. The business's 50-day moving average price is $7.51 and its 200 day moving average price is $8.11. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols, S.A. has a twelve month low of $5.79 and a twelve month high of $9.96. The company has a market capitalization of $5.58 billion, a price-to-earnings ratio of 6.94 and a beta of 0.35.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley initiated coverage on Grifols in a research note on Wednesday, February 12th. They issued an "overweight" rating on the stock.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.